Vigil Neuroscience IPO: When can you buy biotech company's stock?

3 min read | January 04, 2022 04:41 AM EST | By Raza Naqvi

Vigil Neuroscience IPO: When can you buy biotech company's stock? — Image source: Image Source: © Maxxyustas | Megapixl.com

When can you buy Vigil Neuroscience stock?

Vigil Neuroscience is expected to start trading soon in the US equities market, and it will list its common stock on Nasdaq Global Market.

The biotechnology company will trade under the ticker symbol VIGL, and retail investors can buy this stock after Vigil Neuroscience goes public.

Vigil Neuroscience IPO ©2022 Kalkine Media®

According to the amended Form S-1 filed with the US Securities and Exchange Commission (SEC), Vigil Neuroscience has not mentioned if its pre-IPO stock would be up for grabs.

Suppose brokerage companies do not give an option to buy shares before the IPO. In that case, retail investors will have to buy Vigil Neuroscience stock like they buy regular shares through stockbrokers or online trading accounts.

Bottom line

The leading underwriters for Vigil Neuroscience IPO will be Stifel, Morgan Stanley, Guggenheim Securities, and Jefferies.

Vigil Neuroscience gives the underwriters an option to purchase up to 1,050,000 additional shares of the common stock.

The biotechnology company is hoping to raise US$ 101.1 million in gross proceeds of US$ 116.7 million if the underwriters buy all the additional shares.

Vigil Neuroscience plans to use the money raised in the IPO to advance the development of therapies, research, and development of the company's programs.

Also Read: How to buy Fanatics stock as it 'acquires' Topps for $500M?

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.